Medical Oncology

, Volume 28, Issue 4, pp 1530–1533 | Cite as

Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy

Original Paper


Sarcomatoid renal cell cancer is associated with a very poor prognosis, characterized by rapid progression of advanced disease. We previously reported the outcome of 18 patients with advanced sarcomatoid renal cell cancer treated with a regimen consisting of doxorubicin, 50 mg/m2 and gemcitabine, 1,500–2,000 mg/m2, administered every two weeks with growth factor support (A/G). Among the 18 patients, there were two complete and 5 partial responses and two patients with stable disease of more than 6 months of duration. We now report long-term survival of 4 patients with stage IV sarcomatoid renal cell carcinoma treated with this regimen at the 1,500 mg/m2 dose of gemcitabine, and achieving complete response (2 patients), or rendered complete responders following surgery after maximum response (2 patients). The two complete responders are alive, disease free at 6+ and 8+ years after starting A/G, and the 2 patients rendered CR by surgery survived 3½ and 6 years, respectively. Both died of progressive disease, one with clear cell recurrence, one with sarcomatoid recurrence. In summary, this regimen is associated with a high response rate, overall improvement in progression free survival and occasional meaningful long-term survival in a disease expected to be fatal within one year.


Sarcomatoid renal cell cancer Survival Chemotherapy 



Dr. Preston Steen for his excellent care in collaboration of patient 4 and Dr. Peter Wiernik for his review of this manuscript were acknowledged. This work was supported in part by Renal Cancer Research Fund, Cancer Research Foundation.


  1. 1.
    Wu JJ, Caliendo G, Hu X-P, Dutcher JP. Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Med Oncol. 1998;15:44–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167:65–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Tsui KH, Shvarts O, Smith RB, Figline RA, deKernion JB, Belldegrun A. Prgnostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090–4. PMID: 10737472.PubMedCrossRefGoogle Scholar
  4. 4.
    Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Patard JJ, Leray E, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435–41.PubMedCrossRefGoogle Scholar
  8. 8.
    de Peralt-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275–84.CrossRefGoogle Scholar
  9. 9.
    Bangalore N, Bhargava P, Hawkins MJ, et al. Sustained response of sarcomatoid renal cell carcinoma to MAID chemotherapy. Case report and review of the literature. Ann Oncol. 2001;12:271–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Hoshi S, Satoh M, Ohyama C, Hiramatu M, et al. Active chemotherapy for bone metastases in sarcomatoid renal cell carcinoma. Int J Clin Oncol. 2003;8:113–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal cell carcionoma: a treatable entity. Cancer. 1987;60:1313–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Escudier B, Droz JP, Rolland F, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol. 2002;168:959–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004;101:1545–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Haas N, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wildiing G, Dutcher JP : ECOG 8802: a phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features. Proc GU ASCO. 2009.Google Scholar
  15. 15.
    Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419–26.PubMedGoogle Scholar
  16. 16.
    Mertens WC, Eisnehauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1993;4:331–2.PubMedGoogle Scholar
  17. 17.
    deMulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patient with advanced renal cancer. Cancer Chemother Pharmacol. 1996;37:491–5.CrossRefGoogle Scholar
  18. 18.
    Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629–36.PubMedCrossRefGoogle Scholar
  19. 19.
    Neri B, Doni L, Fulignati C, et al. Gemcitabine plus epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage. Anticancer Res. 2002;22:2981–4.PubMedGoogle Scholar
  20. 20.
    Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer. 2002;94:111–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Langner C, von Wasielewski R, Ratschek M, et al. Biological significance of p27 and Skp2 expression in renal cell carcinoma. a systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch. 2004;445:631–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Ishizaki H, Yano H, Tsuneoka M, et al. Overexpression of the mcy target gene Mina53 in advanced renal cell carcinoma. Pathol Int. 2007;57:672–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Visapaa H, Seligson D, Huang Y, et al. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol Res. 2003;30:387–9.PubMedGoogle Scholar
  24. 24.
    Tickoo SK, Alden Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1 alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177:1258–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Tamboli P, Prieto VG, Bekele BN, et al. The tyrosine kinase receptor c-Kit is overexpressed in sarcomatoid renal carcinomas. Proc Am Soc Clin Oncol. 2003;22:408a. (abst 1641).Google Scholar
  26. 26.
    Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2008;27:235–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Michaelson M, Schwarzberg A, Ryan D, McDermott D, Shapiro G, Tye L, Chen I, Selaru P, Wang E, Zhu A. a phase I study of sunitinib in combination with gemcitabine in advanced renal cell carcinoma and other solid tumors. Proc GU ASCO 2008. Abst 362. 2008.Google Scholar
  28. 28.
    Michaelson D, McDermott DF, Atkins MB, Cho DC, Olivier KM, Schwarzberg AB, Choueiri TK: phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor risk metastatic renal cell carcinoma. Proc GU ASCO 2010. Abst 340. 2010.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.OncologyNew York Medical CollegeBronxUSA
  2. 2.OncologyWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations